A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Summary

The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The study is conducted in two parts - phase 1a (dose-escalation, dose-optimization) and phase 1b (dose-expansion). The study will last up to approximately 4 years. Eligible patients will have the option to continue taking study drug after the study is complete.

Timeline

Start

2024-03-05

Primary completion

2027-03

Completion

2027-04

Drugs

Indications